Chardan Capital Has Strong Forecast for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a report issued on Wednesday, May 14th. Chardan Capital analyst R. Li now expects that the company will earn $0.45 per share for the year, up from their prior forecast of ($1.75). Chardan Capital currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million.

Several other research analysts also recently commented on STOK. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. HC Wainwright dropped their price target on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Finally, Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday, May 14th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $23.20.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $9.76 on Monday. The firm has a market cap of $532.87 million, a P/E ratio of -4.65 and a beta of 1.20. The stock’s 50-day moving average is $8.16 and its two-hundred day moving average is $9.94. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $17.58.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in STOK. RTW Investments LP grew its stake in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after buying an additional 471,240 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock valued at $51,111,000 after acquiring an additional 265,395 shares during the last quarter. Toronto Dominion Bank bought a new position in shares of Stoke Therapeutics in the 4th quarter valued at about $35,001,000. Vanguard Group Inc. increased its stake in shares of Stoke Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock worth $18,515,000 after purchasing an additional 53,004 shares during the last quarter. Finally, Siren L.L.C. increased its stake in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock worth $14,945,000 after purchasing an additional 247,347 shares during the last quarter.

Insider Activity

In related news, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This trade represents a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock worth $143,332 over the last three months. Corporate insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.